Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
BACKGROUND Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. METHODS We concluded a randomized trial involving 1088 patients with multiple sclerosis, 18 to 55 years of age, with a score of 0 to 5.5 on the Expanded Disability Status Scale and at least one relapse in the previous year or at least two relapses in the previous 2 years. Patients were ...
متن کاملTeriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first clinical demyelinating event. This review examines the EU SmPC for teriflunomide,...
متن کاملOral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reduction in the accumulation of disability and slowing of the brain volume loss that occurs from the earliest stages of the disease. Teriflunomide, a once-daily, oral immunomodulatory therapy, has demonstrated efficacy across multiple measures of disease activity and worsening in patients with relapsin...
متن کاملTeriflunomide - a new oral agent for multiple sclerosis treatment.
T eriflunomide is an oral immunomo-du lator, an active metabolite of le-flunomide. Leflunomide is used in the long-term treatment of rheuma-toid arthritis and is metabolized to te riflunomide in vivo. The mechanism of action of teriflunomide is linked to reversibly inhibition of dihydroorotate dehydrogenase, a mithocondrial enzyme involved in de novo synthesis of pyrimidine for DNA replication....
متن کاملTeriflunomide for the treatment of multiple sclerosis.
Teriflunomide is a new active drug which has recently been approved as a first-line treatment of relapsing forms of MS in the US, Australia, Argentina, and the European Union. It is characterized by a once-daily oral application and a well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Therapeutics
سال: 2015
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2015.08.003